| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
HTH-01-091 targets maternal embryonic leucine zipper kinase (MELK). MELK is a serine/threonine kinase involved in cell cycle regulation, proliferation, and survival. By inhibiting MELK with high potency (IC50 = 10.5 nM), the compound disrupts these processes in cancer cells. It also inhibits several other kinases, including PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2. Its activity as a 5-HT6 receptor antagonist suggests potential for neurological applications.
|
|---|---|
| ln Vitro |
Over 90% of kinases are specifically inhibited by HTH-01-091 (1 μM) [1]. MELK degradation is caused by cell-permeable HTH-01-091 (0-10 μM, 1 hour) [1]. On breast cancer cells, HTH-01-091 (0–10 μM, 3 days) shows modest anti-proliferative effects [1].
In vitro, HTH-01-091 is a potent MELK inhibitor. It inhibits the growth of cancer cell lines. Its effects on cell proliferation, cell cycle, and apoptosis can be studied in various cancer cell lines. The compound's activity against PIM and other kinases may contribute to its overall antiproliferative effects. It is a valuable tool for studying the role of MELK in cancer and other diseases. |
| ln Vivo |
In vivo, HTH-01-091 can be used for breast cancer research. It is under investigation for its potential use in treating psychiatric and neurological disorders. Its ability to inhibit MELK and other kinases makes it a promising candidate for therapeutic development. Further studies are needed to evaluate its efficacy and safety in animal models of cancer and neurological diseases.
|
| Enzyme Assay |
The in vitro kinase assay for HTH-01-091 involves measuring MELK kinase activity. Recombinant MELK is incubated with varying concentrations of HTH-01-091 (0.01-1000 nM) and a peptide substrate. The incorporation of phosphate is measured using a scintillation proximity assay or a fluorescence-based method. IC50 values are calculated. Selectivity is assessed by testing against a panel of kinases (e.g., PIM1/2/3, RIPK2).
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: MDA-MB-468 Cell Tested Concentrations: 0, 0.1, 1.0 and 10 μM Incubation Duration: 1 hour Experimental Results: diminished MELK protein levels in MDA-MB-468 cells; Streptavidin Beads The pull-down effect on MELK was diminished in a dose-dependent manner, indicating that the compound is cell-permeable and binds to MELK in an ATP-competitive manner. There was no effect on ERK1/2 pulldown, indicating that HTH-01-091 has no binding affinity for ERK1/2. Cell proliferation assay[1] Cell Types: MDA-MB-468, BT-549, HCC70, ZR-75-1, MCF7 and T-47D Cell Tested Concentrations: 0, 0.001, 0.01, 0.1, 1.0 and 10 μM Incubation Duration: 3-day Experimental Results: Demonstrated antiproliferative activity in a panel of breast cancer cell lines, including MDA-MB-468, BT-549, HCC70, ZR-75-1, MCF7, and T-47D cells, with IC50 values of 4.00, respectively. μM, 6.16 μM, 8.80 μM, >10 μM, 8.75 μM and 3.87 μM. In vitro cellular assays for HTH-01-091 use cancer cell lines, such as breast cancer cells. Cells are treated with the compound at concentrations of 0.1-1000 nM for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Cell cycle analysis is performed by flow cytometry. Apoptosis is evaluated using caspase-3/7 activity assays and Annexin V staining. MELK and downstream signaling targets are measured by Western blot. |
| Animal Protocol |
In vivo animal studies for HTH-01-091 involve mouse xenograft models using breast cancer cell lines. Tumor-bearing mice are treated with the compound via oral gavage or intraperitoneal injection at doses of 1-50 mg/kg. Tumor volume is measured regularly. The compound's effect on tumor growth is assessed. Pharmacodynamic studies measure MELK inhibition and downstream signaling in tumor tissues.
|
| ADME/Pharmacokinetics |
HTH-01-091 has a molecular weight of 499.43 and a molecular formula of C26H28Cl2N4O2. It is a potent MELK inhibitor with an IC50 of 10.5 nM. It is used for breast cancer research. The compound is a research tool and is not for human therapeutic use.
|
| References |
| Molecular Formula |
C26H28CL2N4O2
|
|---|---|
| Molecular Weight |
499.432124137878
|
| Exact Mass |
498.158
|
| CAS # |
2000209-42-5
|
| Related CAS # |
HTH-01-091 TFA
|
| PubChem CID |
131801426
|
| Appearance |
White to light yellow solid powder
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
707
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C(=C(C=C(C=1)C1C=CC2=C(C=1)C1=C(C=N2)CNC(N1C1CCC(CN(C)C)CC1)=O)Cl)O
|
| InChi Key |
FUVRHGKKWNNBJX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H28Cl2N4O2/c1-31(2)14-15-3-6-19(7-4-15)32-24-18(13-30-26(32)34)12-29-23-8-5-16(9-20(23)24)17-10-21(27)25(33)22(28)11-17/h5,8-12,15,19,33H,3-4,6-7,13-14H2,1-2H3,(H,30,34)
|
| Chemical Name |
9-(3,5-dichloro-4-hydroxyphenyl)-1-[4-[(dimethylamino)methyl]cyclohexyl]-3,4-dihydropyrimido[5,4-c]quinolin-2-one
|
| Synonyms |
HTH01-091 HTH 01-091 HTH-01-091
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~12.5 mg/mL (~25.0 mM; with ultrasonication and warming by heating to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (2.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0023 mL | 10.0114 mL | 20.0228 mL | |
| 5 mM | 0.4005 mL | 2.0023 mL | 4.0046 mL | |
| 10 mM | 0.2002 mL | 1.0011 mL | 2.0023 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
